| Revenue growth | 21% YoY for FY26; 20% YoY for Q4FY26. |
|---|---|
| Margins | FY26 reported EBITDA margin at 32%, up from 28% YoY. |
| Demand visibility | Positive, driven by 23% YoY growth in tests performed. |
| Management confidence | Strong, emphasizing record high franchisee base and network expansion. |
Growth
FY26 Consolidated Revenue grew 21% YoY to ₹829Cr; PAT jumped 81% YoY to ₹163Cr.
Outlook
Expanding presence in Tanzania and deepening India network; focus on B2B scale efficiencies and specialty tests.
Risks
Margins potentially impacted by increased employee costs from new lab openings and specialty menu investments.
Earnings Call filed with BSE, NSE: THYROCARE. Summary written with AI assistance from the document.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹566.85
- Market cap
- ₹9,022 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 51.2×Sector 57.8×
- Promoter holding
- 60.92%+0.00% QoQ
- FII holding
- 5.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Employee Stock Options
Thyrocare Technologies Limited has granted 1,92,000 employee stock options to eligible employees under the company's approved stock option scheme.
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.
- Value
- ₹141.4 Cr
- Execution
- On or before November 30, 2026
Thyrocare Technologies Share Pledge
API Holdings, successor to promoter Docon, released a full pledge over 7.95 crore Thyrocare shares after NCD redemption. No Docon shares remain encumbered.
Thyrocare Technologies Acquisition
API Holdings Limited reported an exempt acquisition of 8.12 crore shares (51.02%) of Thyrocare Technologies Limited, pursuant to the amalgamation of Docon Technologies Private Limited.
Thyrocare Technologies Promoter Buying (Off-Market)
API Holdings acquired 8,12,00,000 shares (51.02%) of Thyrocare Technologies via a NCLT-approved scheme of amalgamation. The transfer resulted from the merger of Docon Technologies into API Holdings.
- Promoter stake change
- +51.02%
Thyrocare Technologies Earnings Call Transcript: Key Takeaways
Thyrocare Q1 FY27: Consolidated revenue grew 24.3% YoY to INR 240 Cr, EBITDA margin expanded to 32.2%. Strategy shifts toward specialty diagnostics.
- Call
- Guides 18% growth